Shots:

• EUSA to receive up front- up to $160M milestones and royalties on sales of products in the licensed territories.  BeiGene to get an exclusive right to develop & commercialize Sylvant in Greater China and Qarizba in mainland China
• BeiGene will fund and responsible for all clinical development and regulatory submissions in the territories and will launch and commercialize both the therapies following their approvals
•  Qarziba is mAb targeting carbohydrate moiety of disialoganglioside 2 (GD2) currently approved in the EU for the treatment of high-risk neuroblastoma and while Sylvant is mAb targeting IL-6- approved in 40+ countries to treat iMCD. Both the therapies have been listed for NMPA’s FT approval in China

Click here to­ read full press release/ article | Ref: BeiGene | Image: BeiGene